Exelixis initially reaffirmed its full-year 2026 financial guidance in May, highlighting strong early performance and growth in its CABOMETYX drug. However, after reporting second-quarter results with revenue below expectations, the company lowered and narrowed its revenue outlook due to slower-than-expected sales growth in its neuroendocrine tumor segment. This revision led to a decline in Exelixis's stock price and triggered a shareholder investigation into whether the company misled investors about its revenue prospects. Investors who suffered losses may be eligible to participate in the investigation with no upfront cost.
Berkshire Hathaway reported Q2 operating earnings and EPS well above expectations, driven by strong performance in manufacturing, service, and retail segments. Growth was supported by acquisitions and high demand in industrial and aerospace markets. ...
XRP is attracting significant whale accumulation, with 380 million XRP bought near the $1 level, supported by a neutral RSI around 50, unlike other overbought altcoins. Institutional interest is growing, highlighted by Aviva Investors tokenizing a fu...
Worldcoin surged 8.7% to $0.3398, topping the gainers chart with a market cap of $1.22 billion, driven by recent protocol updates. Other notable gainers include Internet Computer, Mantle, World Liberty Financial, and Arbitrum, each benefiting from on...
Bridger Aerospace reported a Q2 loss of $0.13 per share, missing the expected $0.01 loss, with revenue slightly down 1% year-over-year but up 16% excluding non-recurring work. Despite weaker profitability and a net loss of $0.5 million, the company m...
Cantor Fitzgerald downgraded Monday.com from Overweight to Neutral due to concerns about its near-term growth. The company forecasted third-quarter revenue of $368-370 million, below Wall Street's $372.8 million expectation, causing a stock drop. Des...
